益生菌对高PM2.5暴露人群鼻部与肠道菌群影响的随机双盲安慰剂对照试验
BACKGROUND: Extended exposure to high concentrations of PM2.5 changes the human microbiota profile, which in turn may increase morbidity and mortality due to respiratory system damage.…
要点
- 高PM2.5暴露可能改变人类菌群谱,益生菌或可调节微生态并减少呼吸疾病发生。
- 试验以鼻部和肠道菌群16SrRNA测序为主要结局,评估益生菌4周干预效果。
- 次要结局包括肺功能、胃肠道症状评分、生活质量和6个月心血管呼吸终点事件。
核心结论
- 研究旨在探索高PM2.5暴露人群鼻部和肠道菌群特征,并检验益生菌调节菌群平衡、影响肺功能和身体功能及改善生活质量的疗效。
- 研究预期为临床推广益生菌以保护高PM2.5暴露人群提供可靠证据。
研究设计与样本
- 前瞻性、随机、参与者和评估者盲、安慰剂对照试验。
- 干预为连续4周益生菌或安慰剂治疗。
- 主要结局为鼻部和肠道分泌物的16SrRNA测序数据。
- 次要结局包括肺功能、胃肠道症状评定量表评分、COOP/WONCA图表和SF-36生活质量调查。
关键数值与推荐
- 主要结局指标为16SrRNA测序分析鼻部和肠道分泌物。
- 次要结局包括肺功能、胃肠道症状评定量表评分、COOP/WONCA图表和SF-36生活质量调查。
- 6个月随访评估心血管和呼吸疾病终点事件。
临床怎么用
- 该试验尚未报告结果,目前不能提供益生菌用于高PM2.5暴露人群的临床实践推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extended exposure to high concentrations of PM2.5 changes the human microbiota profile, which in turn may increase morbidity and mortality due to respiratory system damage. A balanced microecosystem is crucial to human health, and certain health-related problems may be addressed by effective microecosystem regulation. Recent studies have confirmed that probiotics may reduce the incidence of respiratory diseases. However, few studies have investigated probiotic treatment outcomes in subjects exposed to high concentrations of PM2.5. METHODS: This study is designed as a prospective, randomized, participants- and assessor-blinded, placebo-controlled trial. One hundred and twenty eligible volunteers recruited from October 2019 to July 2020 in downtown Chengdu, China, will be treated with either probiotics or placebo over 4 consecutive weeks. The primary outcome will be 16SrRNA sequencing assay data from nasal and intestinal secretions. Secondary outcomes will be pulmonary function, score on a gastrointestinal symptom rating scale, COOP/WONCA charts, and the Short-Form Health Survey 36 for quality of life. Results will be analyzed to assess differences in clinical efficacy between groups. Six-month follow-up examinations will evaluate the long-term value of probiotics on cardiovascular and respiratory disease end-point events. DISCUSSION: We will explore the characteristics of nasal and intestinal microbiota in a population with high exposure to PM2.5. Probiotics and placebo interventions will be tested for efficacy in microbial balance regulation, effects on lung and physical functions, and quality of life improvement. This study is expected to provide reliable evidence to support the widespread promotion of probiotics in clinical practice for the protection of individuals with high exposure to PM2.5. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900025469 . Registered on 27 August 2019.
引用
- Wu Y, Pei C, Wang X, et al. Effect of probiotics on nasal and intestinal microbiota in people with high exposure to particulate matter ≤ 2.5 μm (PM2.5): a randomized, double-blind, placebo-controlled clinical study. Trials. 2020. PMID: 33054842. doi:10.1186/s13063-020-04759-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。